About Provista Diagnostics
Provista Diagnostics is a Healthcare company based in New York (United States) founded in 2007, and was acquired by Todos Medical in January 2020. Blood-based diagnostic tests for early womens cancer detection are developed. Provista Diagnostics has raised $41.75 million across 13 funding rounds from investors including Todos Medical and Ascenda BioSciences. The company has 2 employees. Provista Diagnostics has completed 1 acquisition, including RCP Diagnostics. Provista Diagnostics offers products and services including Live Draw SDY. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is Provista Diagnostics, Inc. Its competitors include Denali Therapeutics, Poseida Therapeutics and Castle Biosciences; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2007 and based in New York, United States, Provista Diagnostics operates in the molecular oncology sector. Blood-based tests are developed for early recognition of oncology-related diseases, with efforts centered on womens cancers including breast and ovarian types. Proprietary ProteoMark Technology is utilized, integrating serum protein biomarkers, tumor-associated autoantibodies, and patient clinical data to support accurate diagnosis.
- Headquarters New York, United States
- Employees 2
- Stage Acquired
- SectorsHealthcare
- Website provistadx.com
- Social LinkedIn
- Acquired by Todos Medical (Jan 2020)
- Legal Name Provista Diagnostics, Inc.
- Total Equity Funding$41.75M (USD)
in 13 rounds
- InvestorsTodos Medical
& 1 more
- Employee Count2
- Investments & Acquisitions
- Acquired by
Products & Services of Provista Diagnostics
Provista Diagnostics offers a comprehensive portfolio of products and services, including Live Draw SDY.
Provides real-time results and updates for Sydney lottery draws online
Funding Insights of Provista Diagnostics
Provista Diagnostics has successfully raised a total of $41.75M across 13 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $41.75M
- Total Rounds 13
Latest 10 of 13 funding rounds of Provista Diagnostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2018 | Debt – Conventional | – | – | – | |
| May 2018 | $2.21M | Series C | – | – | – |
| Jul 2017 | $2.33M | Series C | – | – | – |
| Jul 2017 | Debt – Conventional | – | – | – | |
| Oct 2016 | $2.56M | Series C | – | – | – |
| Oct 2016 | Debt – Conventional | – | – | – | |
| Mar 2016 | $5.25M | Series C | – | – | – |
| Aug 2015 | $6.05M | Series B | – | – | – |
| Mar 2015 | $3.87M | Series B | – | – | – |
| Apr 2014 | $6M | Series B | – | – | – |
2 investors in total: 2 institutional.
Investors in Provista Diagnostics
Provista Diagnostics has secured backing from 2 investors. Prominent investors backing the company include Todos Medical and Ascenda BioSciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Diagnostic services for microbe detection are provided using PCR-DNA technology. | 2012 | ascendabio.com | Alpharetta, United States | |
Todos Medical is focused on developing diagnostic blood tests. | 2009 | todosmedical.com | Rehovot, Israel |
Investor details for Provista Diagnostics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Provista Diagnostics
4 people are tracked at Provista Diagnostics (4 in leadership); the tracked headcount is 2.
| Name | Role | Group |
|---|---|---|
Elise Brownell | VP of Research & Development | Leadership |
Gerald Commissiong | President | Leadership |
Timothy Seiler | Director of Supply Chain Operations | Leadership |
Jorge Leon | Chief Science Officer | Leadership |
Complete people profiles for Provista Diagnostics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Provista Diagnostics
Provista Diagnostics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include RCP Diagnostics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Blood-based immunoassays for women's cancers were developed. | rcpdiagnostics.com | Phoenix, United States | 2005 | Dec 2006 | •••• |
Complete acquisition details for Provista Diagnostics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Provista Diagnostics
6 dated milestones of Provista Diagnostics across 14 years, from founding to its latest funding, stage changes and deals.
- Acquisition Acquires RCP Diagnostics.
- Founded Provista Diagnostics is founded.
- Funding First funding round.
- Funding Latest funding round, Debt – Conventional,.
- Exit Acquired by Ascenda BioSciences.
- Exit Acquired by Todos Medical.
Competitors of Provista Diagnostics
Provista Diagnostics has 3 listed competitors in our database, 3 of them funded. They include Denali Therapeutics, Poseida Therapeutics and Castle Biosciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | |
| cernostics.com | 2008 | Pittsburgh, United States | $14.18M | 16 | Precision diagnostic and prognostic tests are developed by Castle Biosciences. |
Detailed competitors of Provista Diagnostics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Provista Diagnostics
Websites that share an audience with Provista Diagnostics (provistadx.com).
Websites whose visitors overlap most with Provista Diagnostics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| provista.com | 100% | #2,527,585 | View details | ||
provistaco.com | provistaco.com | 85% | – | ||
| diagnocure.com | 82% | View details | |||
biomerieux-usa.com | biomerieux-usa.com | 80% | #8,600,566 | – | |
| dako.com | 80% | 1.6K | #11,422,431 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Provista Diagnostics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Provista Diagnostics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Provista Diagnostics
Complete news archive for Provista Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Provista Diagnostics
Provista Diagnostics was founded in 2007 and raised its 1st funding round 3 years after it was founded.
Provista Diagnostics is headquartered in New York, United States. It is registered at New York, New York, United States.
Provista Diagnostics is a funded company, having raised a total of $41.75M across 13 funding rounds to date. The company's 1st funding round was a Series B of $6M, raised on May 2010.
Provista Diagnostics has 2 employees.
Founded in 2007 and based in New York, United States, Provista Diagnostics operates in the molecular oncology sector. Blood-based tests are developed for early recognition of oncology-related diseases, with efforts centered on womens cancers including breast and ovarian types. Proprietary ProteoMark Technology is utilized, integrating serum protein biomarkers, tumor-associated autoantibodies, and patient clinical data to support accurate diagnosis.
Provista Diagnostics's top competitors include Poseida Therapeutics, Denali Therapeutics and Castle Biosciences.
Provista Diagnostics offers Live Draw SDY.
Provista Diagnostics has made 1 acquisition, including RCP Diagnostics.
Provista Diagnostics has 2 investors. Key investors include Todos Medical, and Ascenda BioSciences.
Provista Diagnostics operates through Provista Diagnostics, Inc..
Yes. Provista Diagnostics was acquired by Todos Medical in January 2020.